Carregant...
Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico
Background: Ten to fifteen percent of patients with myasthenia gravis (MG) have treatment-refractory disease. In short series and case reports, rituximab has proven to be effective in refractory MG. Methods: A retrospective, longitudinal study was conducted. Recruitment was performed in an MG cohort...
Guardat en:
| Publicat a: | Cureus |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cureus
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7946608/ https://ncbi.nlm.nih.gov/pubmed/33728176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.13226 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|